GW cashes in on Epidiolex data with $148m public offering
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals has priced a public offering on NASDAQ of 1.7m American Depository Shares (ADSs) at $86.83 each to raise $148m following positive results from a physician-led study of cannabidiol epilepsy drug Epidiolex.